Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24938255 | 1.00 | CRBN (0.70) | CRBNDDB1TNFIL1BTBXA2R | |
| Hydrochloric Acid SCHEMBL2399619 | 0.99 | CRBN (0.69) | CRBNDDB1TNFIL1BTBXA2R | |
| Hydrochloric Acid SCHEMBL2382665 | 0.99 | CRBN (0.69) | CRBNDDB1TNFIL1BTBXA2R | |
| Trifluoroacetic Acid SCHEMBL18448754 | 0.94 | CRBN (0.63) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL2384835 | 0.94 | DDB1 (0.77) | CRBNDDB1TNFIL1BTBXA2R | |
| Hydrochloric Acid SCHEMBL2383396 | 0.93 | DDB1 (0.75) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL3783534 | 0.92 | CRBN (0.72) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL2381344 | 0.91 | CRBN (0.73) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL501757 | 0.91 | CRBN (0.73) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL29808178 | 0.91 | CRBN (0.73) | CRBNDDB1TNFIL1BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | claimed |
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | claimed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | claimed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-7576104-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| US-7091353-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CRBN 1511/4885DDB1 3650/4885TNF 1/4885 |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | TNF, IKZF3, TNFRSF1A | CRBN 1695/4885DDB1 3627/4885TNF 1/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CRBN 1511/4885DDB1 3650/4885TNF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.